April 30, 2013
/PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has appointed
Deborah M. Autor
as senior vice president, Strategic Global Quality and Regulatory Policy. Autor joins Mylan from the U.S. Food and Drug Administration (FDA), where she served for 11 years, most recently as deputy commissioner for Global Regulatory Operations and Policy. At Mylan, Autor will focus on further advancing Mylan's efforts to lead the industry in establishing one global quality standard for pharmaceutical products and expanding the world's access to high quality medicine.
commented, "We are thrilled to welcome Deb to Mylan in this unique role and believe that her experience, dedication and commitment to advancing global quality standards at FDA align with Mylan's commitment to ensuring one high quality standard for our products wherever they are made. Deb's insights into the challenges of globalization to the health care sector will be extremely valuable as we continue to seek to raise the bar on quality standards for the industry around the world. Our goal is to ensure that anyone taking medicine anywhere can be confident in the quality standards used to produce it."
added, "Mylan's reputation for quality has distinguished our company since its founding more than 50 years ago and helped fuel our growth into a global pharmaceutical leader. We believe Deb's decision to join Mylan speaks to the culture of quality she has seen embedded within our organization and believe that Deb can help further differentiate Mylan from its competitors in terms of quality, integrity and service as we seek to provide the world's 7 billion people with access to high quality medicine."
Autor commented, "Mylan has been a leading advocate for ensuring one quality standard, both internally and externally, as evidenced by the company's active role in the development and passage of the FDA Safety and Innovation Act, or FDASIA. I am very excited to be joining an organization whose people demonstrate such extraordinary passion and commitment to quality and access to medicine. I look forward to contributing to Mylan's continued leadership on quality – both from an operational and policy perspective."